185 related articles for article (PubMed ID: 37122718)
1. The catalytic inhibitor epacadostat can affect the non-enzymatic function of IDO1.
Panfili E; Mondanelli G; Orabona C; Gargaro M; Volpi C; Belladonna ML; Rossini S; Suvieri C; Pallotta MT
Front Immunol; 2023; 14():1134551. PubMed ID: 37122718
[TBL] [Abstract][Full Text] [Related]
2. Epacadostat stabilizes the apo-form of IDO1 and signals a pro-tumorigenic pathway in human ovarian cancer cells.
Rossini S; Ambrosino S; Volpi C; Belladonna ML; Pallotta MT; Panfili E; Suvieri C; Macchiarulo A; Mondanelli G; Orabona C
Front Immunol; 2024; 15():1346686. PubMed ID: 38333210
[TBL] [Abstract][Full Text] [Related]
3. Reimagining IDO Pathway Inhibition in Cancer Immunotherapy via Downstream Focus on the Tryptophan-Kynurenine-Aryl Hydrocarbon Axis.
Labadie BW; Bao R; Luke JJ
Clin Cancer Res; 2019 Mar; 25(5):1462-1471. PubMed ID: 30377198
[TBL] [Abstract][Full Text] [Related]
4. Indoleamine 2,3-dioxygenase (IDO) inhibitors and cancer immunotherapy.
Fujiwara Y; Kato S; Nesline MK; Conroy JM; DePietro P; Pabla S; Kurzrock R
Cancer Treat Rev; 2022 Nov; 110():102461. PubMed ID: 36058143
[TBL] [Abstract][Full Text] [Related]
5. Target exposure and pharmacodynamics study of the indoleamine 2,3-dioxygenase-1 (IDO-1) inhibitor epacadostat in the CT26 mouse tumor model.
Poncelet L; Ait-Belkacem R; Marillier R; Gomes B; Stauber J
J Pharm Biomed Anal; 2019 Jun; 170():220-227. PubMed ID: 30933897
[TBL] [Abstract][Full Text] [Related]
6. Inhibiting IDO pathways to treat cancer: lessons from the ECHO-301 trial and beyond.
Muller AJ; Manfredi MG; Zakharia Y; Prendergast GC
Semin Immunopathol; 2019 Jan; 41(1):41-48. PubMed ID: 30203227
[TBL] [Abstract][Full Text] [Related]
7. Indoleamine 2,3-dioxygenase 1 in circumventing checkpoint inhibitor responses: Updated.
Charehjoo A; Majidpoor J; Mortezaee K
Int Immunopharmacol; 2023 May; 118():110032. PubMed ID: 36933494
[TBL] [Abstract][Full Text] [Related]
8. Updates in the Clinical Development of Epacadostat and Other Indoleamine 2,3-Dioxygenase 1 Inhibitors (IDO1) for Human Cancers.
Komiya T; Huang CH
Front Oncol; 2018; 8():423. PubMed ID: 30338242
[TBL] [Abstract][Full Text] [Related]
9. Dual-target inhibitors of indoleamine 2, 3 dioxygenase 1 (Ido1): A promising direction in cancer immunotherapy.
Zhang Y; Hu Z; Zhang J; Ren C; Wang Y
Eur J Med Chem; 2022 Aug; 238():114524. PubMed ID: 35696861
[TBL] [Abstract][Full Text] [Related]
10. The IDO1 selective inhibitor epacadostat enhances dendritic cell immunogenicity and lytic ability of tumor antigen-specific T cells.
Jochems C; Fantini M; Fernando RI; Kwilas AR; Donahue RN; Lepone LM; Grenga I; Kim YS; Brechbiel MW; Gulley JL; Madan RA; Heery CR; Hodge JW; Newton R; Schlom J; Tsang KY
Oncotarget; 2016 Jun; 7(25):37762-37772. PubMed ID: 27192116
[TBL] [Abstract][Full Text] [Related]
11. Epacadostat Plus Pembrolizumab and Chemotherapy for Advanced Solid Tumors: Results from the Phase I/II ECHO-207/KEYNOTE-723 Study.
Powderly JD; Klempner SJ; Naing A; Bendell J; Garrido-Laguna I; Catenacci DVT; Taylor MH; Lee JJ; Zheng F; Zhou F; Gong X; Gowda H; Beatty GL
Oncologist; 2022 Nov; 27(11):905-e848. PubMed ID: 36156099
[TBL] [Abstract][Full Text] [Related]
12. IDO1 Is a Therapeutic Target for Pancreatic Cancer-Associated Depression.
Hue JJ; Graor HJ; Zarei M; Katayama ES; Ji K; Hajihassani O; Loftus AW; Vaziri-Gohar A; Winter JM
Mol Cancer Ther; 2022 Dec; 21(12):1810-1822. PubMed ID: 36190971
[TBL] [Abstract][Full Text] [Related]
13. What is the prospect of indoleamine 2,3-dioxygenase 1 inhibition in cancer? Extrapolation from the past.
Yao Y; Liang H; Fang X; Zhang S; Xing Z; Shi L; Kuang C; Seliger B; Yang Q
J Exp Clin Cancer Res; 2021 Feb; 40(1):60. PubMed ID: 33557876
[TBL] [Abstract][Full Text] [Related]
14. Tryptophan: A Rheostat of Cancer Immune Escape Mediated by Immunosuppressive Enzymes IDO1 and TDO.
Kim M; Tomek P
Front Immunol; 2021; 12():636081. PubMed ID: 33708223
[TBL] [Abstract][Full Text] [Related]
15. A randomised, open-label, phase 2 study of the IDO1 inhibitor epacadostat (INCB024360) versus tamoxifen as therapy for biochemically recurrent (CA-125 relapse)-only epithelial ovarian cancer, primary peritoneal carcinoma, or fallopian tube cancer.
Kristeleit R; Davidenko I; Shirinkin V; El-Khouly F; Bondarenko I; Goodheart MJ; Gorbunova V; Penning CA; Shi JG; Liu X; Newton RC; Zhao Y; Maleski J; Leopold L; Schilder RJ
Gynecol Oncol; 2017 Sep; 146(3):484-490. PubMed ID: 28698009
[TBL] [Abstract][Full Text] [Related]
16. Targeting Indoleamine 2,3-Dioxygenase in Cancer Models Using the Novel Small Molecule Inhibitor NTRC 3883-0.
Grobben Y; de Man J; van Doornmalen AM; Muller M; Willemsen-Seegers N; Vu-Pham D; Mulder WR; Prinsen MBW; de Wit J; Sterrenburg JG; van Cauter F; den Ouden JE; van Altena AM; Massuger LF; Uitdehaag JCM; Buijsman RC; Zaman GJR
Front Immunol; 2020; 11():609490. PubMed ID: 33584686
[TBL] [Abstract][Full Text] [Related]
17. First-in-Human Phase I Study of the Oral Inhibitor of Indoleamine 2,3-Dioxygenase-1 Epacadostat (INCB024360) in Patients with Advanced Solid Malignancies.
Beatty GL; O'Dwyer PJ; Clark J; Shi JG; Bowman KJ; Scherle PA; Newton RC; Schaub R; Maleski J; Leopold L; Gajewski TF
Clin Cancer Res; 2017 Jul; 23(13):3269-3276. PubMed ID: 28053021
[No Abstract] [Full Text] [Related]
18. Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study.
Long GV; Dummer R; Hamid O; Gajewski TF; Caglevic C; Dalle S; Arance A; Carlino MS; Grob JJ; Kim TM; Demidov L; Robert C; Larkin J; Anderson JR; Maleski J; Jones M; Diede SJ; Mitchell TC
Lancet Oncol; 2019 Aug; 20(8):1083-1097. PubMed ID: 31221619
[TBL] [Abstract][Full Text] [Related]
19. Phase 1/2 study of epacadostat in combination with ipilimumab in patients with unresectable or metastatic melanoma.
Gibney GT; Hamid O; Lutzky J; Olszanski AJ; Mitchell TC; Gajewski TF; Chmielowski B; Hanks BA; Zhao Y; Newton RC; Maleski J; Leopold L; Weber JS
J Immunother Cancer; 2019 Mar; 7(1):80. PubMed ID: 30894212
[TBL] [Abstract][Full Text] [Related]
20. Indoleamine 2,3-Dioxygenase 1 Inhibitor-Loaded Nanosheets Enhance CAR-T Cell Function in Esophageal Squamous Cell Carcinoma.
Shao J; Hou L; Liu J; Liu Y; Ning J; Zhao Q; Zhang Y
Front Immunol; 2021; 12():661357. PubMed ID: 33828565
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
